Exabis Library
Welcome to the e-CCO Library!
OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:21 PM by Vesna Babaja
1
OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:22 PM by Vesna Babaja
1
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:34 PM by ECCO Administrator
1
OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial
2021
ECCO'21 Virtual
Friday, 1 October 2021, 12:41 PM
OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP01: PROFILE: a multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed Crohn’s disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn’s disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:33 PM by ECCO Administrator
1
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate- severe flares: A multi-center, randomised, double-blind, sham- controlled trial
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:31 PM by ECCO Administrator
1
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:30 PM by ECCO Administrator
1
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:28 PM by ECCO Administrator
1
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:27 PM by ECCO Administrator
1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:24 PM by ECCO Administrator
1